Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01532336 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis
A Phase 2 study, sponsored by NovaBay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
NCT01532336: Completed Phase 2 study, sponsored by NovaBay Pharmaceuticals.
NCT01532336 is a Phase 2 study that has completed, run by NovaBay Pharmaceuticals. The registered enrollment target is 500 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01532336, a Phase 2 study, has completed, sponsored by NovaBay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical and microbiological efficacy and safety of NVC-422 compared to vehicle for adenoviral conjunctivitis. Adults and children one year of age and older with diagnosis of adenoviral conjunctivitis in at least one eye based upon a positive adenovirus test result using the Aden-Detactor Plus kit (Rapid Pathogen Screening, Inc). Subjects will be randomly assigned to receive either NVC-422 or Vehicle.
Interventions
- DRUG NVC-422 Solution, 0.3%
- DRUG NVC-422 Vehicle Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
What the finished NCT01532336 record still lists
NCT01532336 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher).
The record links to 0 conditions, and to 2 interventions - of which NVC-422 Solution, 0.3% is the first listed.
NCT01532336 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01532336 about?
NCT01532336 is a clinical study titled "Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis". The purpose of this study is to evaluate the clinical and microbiological efficacy and safety of NVC-422 compared to vehicle for adenoviral conjunctivitis. Adults and children one year of age and older with diagnosis of adenoviral conjunctivitis in at least one eye based upon a positive adenovirus t...
What is the current status of trial NCT01532336?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2012-05. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01532336?
The interventions under investigation include: NVC-422 Solution, 0.3% (DRUG), NVC-422 Vehicle Solution (DRUG).
Who is sponsoring clinical trial NCT01532336?
This trial is sponsored by NovaBay Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01532336's enrollment target sits among peer trials
500 70th of 2000 higher than 1,927 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia